Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AlpC is a bacterial actin-like protein primarily identified in species such as Bacillus subtilis and certain pathogenic bacteria, where it plays a critical role in the stable inheritance of low-copy-number plasmids. It functions by polymerizing into dynamic filaments that physically push or pull plasmid DNA to opposite poles of the cell during division, a process driven by ATP hydrolysis. Because AlpC is essential for the maintenance of plasmids that often carry virulence factors and antibiotic resistance genes, it is considered an emerging target for novel antimicrobial strategies. Disrupting AlpC polymerization or its interaction with adapter proteins like AlpR can lead to plasmid loss, thereby reducing bacterial pathogenicity and reversing drug resistance. While no clinical drugs currently target AlpC, its distinct structural differences from eukaryotic actin make it a viable candidate for selective inhibition.
Inhibition of filament polymerization or ATP-binding pocket disruption to prevent plasmid inheritance and bacterial fitness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actin-like protein AlpC (AlpC).